555,999 Shares in Smith & Nephew SNATS, Inc. $SNN Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the second quarter, HoldingsChannel.com reports. The firm bought 555,999 shares of the medical equipment provider’s stock, valued at approximately $34,872,000.

Several other institutional investors and hedge funds have also modified their holdings of SNN. Clearstead Trust LLC bought a new stake in Smith & Nephew SNATS in the 2nd quarter valued at about $25,000. Garner Asset Management Corp acquired a new position in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $27,000. Arax Advisory Partners increased its holdings in shares of Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 569 shares during the period. Advisors Asset Management Inc. bought a new position in shares of Smith & Nephew SNATS during the fourth quarter worth approximately $36,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Smith & Nephew SNATS during the third quarter worth approximately $41,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a research note on Monday, May 11th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Monday. Two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Trading Up 0.3%

Shares of NYSE:SNN opened at $29.32 on Thursday. Smith & Nephew SNATS, Inc. has a one year low of $28.56 and a one year high of $38.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. The firm has a 50 day simple moving average of $30.26 and a 200 day simple moving average of $31.74.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be issued a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.